LivaNova price to free cash flow LIVN
Market value divided by free cash flow over the last twelve months, since 2017.
- Today, Nov 2, 2026
- 29.8×
- 10-year median
- 51.9×
- Against its 10-year history
- 24th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 13.6× to 369×
- Peer median
- 22.8×
LivaNova's price to free cash flow is 29.8× as of Nov 2, 2026.
That is below its ten-year median of 51.9×, lower than on 76% of days in the last ten years.
Over that time it ranged from 13.6× in Apr 2025 to 369× in Jun 2021.
The median for 6 medical device stocks of a similar size is 22.8×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 29.8× | 17.3× | 30.5× |
| 2025 | 17.9× | 13.6× | 25.0× |
| 2024 | 23.3× | 23.3× | 364× |
| 2023 | 329× | 43.7× | 330× |
| 2022 | 49.8× | 36.5× | 68.5× |
| 2021 | 57.0× | 52.2× | 369× |
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 189× | 39.2× | 217× |
| 2018 | 52.8× | 48.3× | 118× |
| 2017 | 47.7× | 34.8× | 52.5× |
Against its peers
Companies in Medical - Devices nearest LivaNova's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| LIVNLivaNova | 29.8× |
| ITGRInteger | 52.6× |
| TMDXTransMedics | 29.2× |
| CNMDCONMED | 10.5× |
| ZBHZimmer Biomet | 12.2× |
| DXCMDexCom | 22.7× |
| GEHCGE HealthCare Technologies | 22.8× |
| Peer median | 22.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on LivaNova
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.